# Apollomics

Source: https://onco.cc/companies/apollomics/  
OnCo record `apollomics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Apollomics is a US-Chinese company whose MET inhibitor vebreltinib is approved in China for MET exon 14 lung cancer through its partner Avistone, and whose E-selectin antagonist uproleselan failed in acute myeloid leukaemia in 2024.

## Summary

Apollomics, based in Foster City, California with operations in Hangzhou and listed on Nasdaq since a 2023 merger, licenses and develops cancer drugs. Vebreltinib (APL-101, bozitinib), a selective MET inhibitor, is approved in China for MET exon 14 skipping non-small-cell lung cancer via Avistone; the phase 3 trial of uproleselan, an E-selectin antagonist licensed from GlycoMimetics, with chemotherapy in relapsed acute myeloid leukaemia missed its survival endpoint in 2024. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Apollomics Inc.; Apollomics (Hangzhou)
- Tags: ctgov-sponsor
- HQ: Foster City, CA
- Type: biotech
- Website: https://www.apollomicsinc.com

## Sources

- Official website: https://www.apollomicsinc.com
- ClinicalTrials.gov: trials led by Apollomics: https://clinicaltrials.gov/search?lead=Apollomics

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [MET](https://onco.cc/targets/met/)
- companies: [Avistone Biotechnology](https://onco.cc/companies/avistone-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/apollomics.json